Main findings
In this meta-analysis and meta-regression, pravastatin usage for uteroplacental insufficiency was associated with a significant prolongation of pregnancy, mean 0.44 weeks, from study entry to delivery. Prematurity is the main cause of neonatal mortality, and early neonatal as well as late childhood morbidity. Preventing preterm births has been delineated as one of the most urgent goals in current obstetrics. Prolonging pregnancy has most probably resulted in the significant decrease observed in NICU admission, and the trends towards decreased perinatal death and increased neonatal birth weight. In addition, a sensitivity analysis that excluded Döbert et al study, that selected women only in their late third trimester, new onset of preeclampsia was less common under pravastatin treatment.